Real-World Outcomes of Transcatheter Tricuspid Valve Replacement

JAMAPublished 12 May 2026

Authors' conclusion

Early US real-world experience with TTVR confirms safety and effectiveness in patients with severe TR.

Study context

Population: Patients with symptomatic, severe tricuspid regurgitation (TR) despite optimal medical therapy, transcatheter tricuspid valve replacement (TTVR) deemed appropriate by a heart team, US STS/ACC TVT Registry, February 2024 – March 2025
Participants: 1,034 attempted procedures

Outcome: Event rates (all-cause death, stroke, bleeding, new CIED implantation, HF hospitalization), TR reduction and changes in health status (NYHA class, KCCQ-OS score)
Follow-up: 30 days

As reported in the abstract

30-day clinical, echocardiographic and health status outcomes

Valve successfully implanted: 1017 patients (98.4%)
Mild or less TR post procedure: 98.4%
Mild or less TR at 30 days: 97.7%
NYHA class I/II at 30 days (improvement from baseline): 82.7%; P < .001
Mean KCCQ-OS score improvement, baseline to 30 days: 22.4 points; P < .001
No significant differences by baseline CIED status: 30-day mortality: P = .47
No significant differences by baseline CIED status: HF hospitalization: P > .99
No significant differences by baseline CIED status: functional outcomes: P = .55

Observational data: associations, not effects.

30-day outcomes by baseline CIED status (subgroup)

30-day event rates

Real-World Outcomes of Transcatheter Tricuspid Valve Replacement. JAMA. Published 12 May 2026. doi:10.1001/jama.2026.3446

Summarised from the published abstract; every number is checked against it